214 related articles for article (PubMed ID: 12657934)
1. Galectin-3 expression in hyalinizing trabecular tumors of the thyroid gland.
Gaffney RL; Carney JA; Sebo TJ; Erickson LA; Volante M; Papotti M; Lloyd RV
Am J Surg Pathol; 2003 Apr; 27(4):494-8. PubMed ID: 12657934
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.
Jakubiak-Wielganowicz M; Kubiak R; Sygut J; Pomorski L; Kordek R
Pol J Pathol; 2003; 54(2):111-5. PubMed ID: 14575419
[TBL] [Abstract][Full Text] [Related]
3. Value of immunohistochemical expression of p27 and galectin-3 in differentiation between follicular adenoma and follicular carcinoma.
Abulkheir IL; Mohammad DB
Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):131-40. PubMed ID: 22553813
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
[TBL] [Abstract][Full Text] [Related]
5. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
6. Galectin-3 is a presurgical marker of human thyroid carcinoma.
Orlandi F; Saggiorato E; Pivano G; Puligheddu B; Termine A; Cappia S; De Giuli P; Angeli A
Cancer Res; 1998 Jul; 58(14):3015-20. PubMed ID: 9679965
[TBL] [Abstract][Full Text] [Related]
7. RET/PTC activation in hyalinizing trabecular tumors of the thyroid.
Papotti M; Volante M; Giuliano A; Fassina A; Fusco A; Bussolati G; Santoro M; Chiappetta G
Am J Surg Pathol; 2000 Dec; 24(12):1615-21. PubMed ID: 11117781
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue.
Cvejic D; Savin S; Paunovic I; Tatic S; Havelka M; Sinadinovic J
Anticancer Res; 1998; 18(4A):2637-41. PubMed ID: 9703921
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions.
Herrmann ME; LiVolsi VA; Pasha TL; Roberts SA; Wojcik EM; Baloch ZW
Arch Pathol Lab Med; 2002 Jun; 126(6):710-3. PubMed ID: 12033961
[TBL] [Abstract][Full Text] [Related]
10. Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas.
Nascimento MC; Bisi H; Alves VA; Longatto-Filho A; Kanamura CT; Medeiros-Neto G
Endocr Pathol; 2001; 12(3):275-9. PubMed ID: 11740048
[TBL] [Abstract][Full Text] [Related]
11. Cell membrane and cytoplasmic staining for MIB-1 in hyalinizing trabecular adenoma of the thyroid gland.
Hirokawa M; Carney JA
Am J Surg Pathol; 2000 Apr; 24(4):575-8. PubMed ID: 10757406
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential.
Papotti M; Rodriguez J; De Pompa R; Bartolazzi A; Rosai J
Mod Pathol; 2005 Apr; 18(4):541-6. PubMed ID: 15529186
[TBL] [Abstract][Full Text] [Related]
13. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma.
Maruta J; Hashimoto H; Yamashita H; Yamashita H; Noguchi S
Diagn Cytopathol; 2004 Dec; 31(6):392-6. PubMed ID: 15540177
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.
Saggiorato E; Aversa S; Deandreis D; Arecco F; Mussa A; Puligheddu B; Cappia S; Conticello S; Papotti M; Orlandi F
J Endocrinol Invest; 2004 Apr; 27(4):311-7. PubMed ID: 15233548
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions.
Kim MJ; Kim HJ; Hong SJ; Shong YK; Gong G
Acta Cytol; 2006; 50(1):28-34. PubMed ID: 16514837
[TBL] [Abstract][Full Text] [Related]
16. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
17. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
Aron M; Kapila K; Verma K
Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
[TBL] [Abstract][Full Text] [Related]
18. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T
Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421
[TBL] [Abstract][Full Text] [Related]
19. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
[TBL] [Abstract][Full Text] [Related]
20. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
